[Translation] A Phase 1b/2, dose-escalation, and cohort expansion study evaluating the safety and efficacy of BGB-11417 alone, BGB-11417 plus dexamethasone, BGB-11417 plus dexamethasone and carfilzomib, dexamethasone and daratumumab, and dexamethasone and pomalidomide in patients with relapsed/refractory multiple myeloma harboring t(11;14)
第一部分主要目的:
评价Sonrotoclax联合地塞米松与Sonrotoclax联合地塞米松和卡非佐米、地塞米松和达雷妥尤单抗以及地塞米松和泊马度胺治疗携带t(11;14)的R/R MM患者的安全性和耐受性;
确定Sonrotoclax联合地塞米松与Sonrotoclax联合地塞米松和卡非佐米、地塞米松和达雷妥尤单抗以及地塞米松和泊马度胺治疗携带t(11;14)的R/R MM患者的最大耐受剂量(MTD)/最大评估剂量(MAD)和初步2期推荐剂量(RP2D); 第二部分主要目的: 评价在RP2D下Sonrotoclax单药与Sonrotoclax联合地塞米松治疗携带t(11;14)的R/R MM患者的安全性和耐受性;
评价Sonrotoclax联合地塞米松和卡非佐米在推荐剂量组合下治疗携带t(11;14)的R/R MM患者的安全性和耐受性;
通过总缓解率和其他缓解率指标评估Sonrotoclax单药、Sonrotoclax联合地塞米松、Sonrotoclax联合地塞米松和卡非佐米治疗携带t(11;14)的R/R MM患者的有效性。
[Translation] The main objectives of the first part:
To evaluate the safety and tolerability of Sonrotoclax combined with dexamethasone, Sonrotoclax combined with dexamethasone and carfilzomib, dexamethasone and daratumumab, and dexamethasone and pomalidomide in the treatment of R/R MM patients with t(11;14);
To determine the maximum tolerated dose (MTD)/maximum assessed dose (MAD) and preliminary phase 2 recommended dose (RP2D) of Sonrotoclax combined with dexamethasone, Sonrotoclax combined with dexamethasone and carfilzomib, dexamethasone and daratumumab, and dexamethasone and pomalidomide in the treatment of R/R MM patients with t(11;14); The main objectives of the second part: To evaluate Sonrotoclax alone and Sonrotoclax combined with dexamethasone in the treatment of R/R MM patients with t(11;14) under RP2D Safety and tolerability in MM patients;
Evaluate the safety and tolerability of Sonrotoclax combined with dexamethasone and carfilzomib in the treatment of R/R MM patients with t(11;14) at the recommended dose combination;
Evaluate the efficacy of Sonrotoclax alone, Sonrotoclax combined with dexamethasone, and Sonrotoclax combined with dexamethasone and carfilzomib in the treatment of R/R MM patients with t(11;14) by overall response rate and other response rate indicators.